Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide

Nucleic Acid Therapeutics

Volumn 24, Issue 4, 2014, Pages 267-282

  Franco, Raúl ^a   Rodriguez, Juan M ^b   Elías, Fernanda ^a   Hernando Insúa, Andrés ^b   Fló, Juan ^a   López, Ricardo ^a   Nagle, Carlos ^c   Lago, Néstor ^d   Zorzopulos, Jorge ^a   Horn, David L ^e   Montaner, Alejandro D ^f  

^a Immunotech SA   (Argentina)

^b Fundacion Pablo Cassara   (Argentina)

^c CEMIC   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e David Horn LLC   (United States)

^f Instituto de Ciencia y Tecnología Dr Cesar Milstein   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; COMPLEMENT; IMT 504; OLIGODEOXYNUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG SAFETY; FEMALE; HAPLORHINI; IMMUNOSTIMULATION; INFLAMMATION; LEUKOCYTE COUNT; LIVER INJURY; LIVER WEIGHT; LYMPHOID HYPERPLASIA; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN WEIGHT; SPLENOMEGALY;

ANIMALS; CEBUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; FEMALE; IMMUNOLOGIC FACTORS; INFLAMMATION; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; OLIGODEOXYRIBONUCLEOTIDES; RATS; SEX FACTORS; SPLENOMEGALY;

EID: 84904904159     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2013.0479     Document Type: Article

References (40)

1. Agrawal, S., Temsamani, J. and TANG, J.Y. (1991). Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. U. S. A. 88, 7595-7599 (Pubitemid 21915200)
2. Bianchi, M.S., Hernando-Insú A. A., Chasseing, N. A., Rodríguez, J. M., ElíAS, F., Lago, N., Zorzopulos, J., Libertun, C., Montaner, A.D., aND Lux-Lantos, V.A. (2010). ODN IMT504 induces a marked recovery in a STZ-induced model of diabetes in rats: Correlation with an early increase in the expression of Nestin and Neurogenin 3 progenitor cell markers. Diabetologia 53, 1184-1189
3. Bode, C., Zhao, G., Steinhagen, F., Kinjo, T., aND Klinman, D. M. (2011). CpG DNA as a vaccine adjuvant. Expert. Rev. Vaccines 10, 499-511
4. Center FOR DRUG EVALUATION AND RESEARCH (CDER). (2010). Guidance for Industry M3(R2): Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. (Food and Drug Administration, Washington DC). Available online at: Www .fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/default.htm
5. Cornish, K.G., Iversen, P., Smith, L., Arneson, M., aND Bayever, E.C. (1993). Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesusmonkey. Pharmacol.Commun. 3, 239-247 (Pubitemid 23237834)
6. Coronel, M.F., Hernando, A., Rodriguez, J., Chasseing, N., Montaner, A., aND Villar, M. (2008). ODN IMT504 reduces neuropathic pain after peripheral nerve injury. Neuroscience Lett. 444, 69-73
7. ElíAS, F., Fló , J., Lopez, R.A., Zorzopulos, J., Montaner, A., aND Rodriguez, J.M. (2003). Strong cytosineguanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J. Immunol. 171, 3697-3704 (Pubitemid 37254574)
8. ElíAS, F., Flo, J., Rodriguez, J M., De Nichilo, A., Lopez, R. A., Zorzopulos, J., Nagle, C., Lahoz, M., aND Montaner, A. (2005). PyNTTTTGT prototype oligonucleotide IMT504 is a potent adjuvant for the recombinant Hepatitis B vaccine that enhances the Th1 response.Vaccine 23, 3597-3603 (Pubitemid 40602795)
9. Galbraith, W.M., Hobson, W.C., Giclas, P.C., Schechter, P.J., aND Agrawal, S. (1994). Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4, 201-206
10. Gan, Z., Huali, J., Jinyao, L., Baowei, S., Xiaogang, D., Youmin, K., Xiao, W., aND Bin, W. (2009). PyNTTTTGT prototype oligonucleotide IMT504, a Novel effective adjuvant of the FMDV DNA vaccine. Viral Immunol. 22, 131-138
11. Gatehouse, D., Haworth, S., Cebula, T., Gocke, E., Kier, L., Matsushima, T., Melcion, C., Nohmi, T., Ohta, T., Venitt, S, et al. (1994). Recommendations for the performance of bacterial mutation assays. Mutat. Res. 312, 217-233 (Pubitemid 24187385)
12. Gupta, C. (2012). Study of acute, subacute and chronic toxicity test. IJARPB 1, 103-129
13. Halperin, S.A., Mcneil, S., Langley, J.M., Smith, B., Mackinnon-CAMERON, D., Mccall-SANI, R., Heyward, W.L, and MARTIN JT. (2012) Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-Administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine 30, 5445-5448
14. Halperin, S.A., Ward, B., Cooper, C., Predy, G., Diaz-Mitoma, F., Dionne, M., Embree, J., Mcgeer, A., Zickler, P., Moltz, KH., et al. (2012b) Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-Administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 30, 2556-2563
15. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., aND Kira, S. (2000). A tolllike receptor recognizes bacterial DNA. Nature 408, 740-745 (Pubitemid 32015992)
16. Henry, S.P., Bolte, H., Auletta, C., aND Kornbrust, D.J. (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.Toxicology 120, 145-155 (Pubitemid 27223345)
17. Hernando-Insú A, A., Montaner, A.D., Rodriguez, J.M., Elias, F., Fló , J., Ló pez, R.A., Zorzopulos, J., Hofer, E.L., aND Chasseing, N.A. (2007). IMT504, the prototype of the immunostimulatory oligonucleotides of the PyNTTTTGT class, increases the number of progenitors of mesenchymal stem cells both in vitro and in vivo: Potential use in tissue repair therapy. Stem Cells 25, 1047-1054 (Pubitemid 46572603)
18. Hernando-Insu ́ A, A., Rodriguez, J.M., Elías, F., Fló , J., Ló pez, R., Franco, R., Lago, N., Zorzopulos, J., aND Montaner, A.D. (2010). A high dose of IMT504, the PyNTTTTGT prototype immunostimulatory ODN, does not alter embryonic development in rats. Oligonucleotides 20, 33-36
19. Heyward, W.L., Kyle, M., Blumenau, J., Davis, M., Reisinger, K., Kabongo, M.L, Bennett, S., Janssen, R.S., Namini, H., aND Martin, J.T. (2013). Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. Vaccine 31, 5300-5305
20. Hofmann, M.A., Kors, C., Audring, H., Walden, P., Sterry, W., aND Trefzer, U. (2008). Phase 1 evaluation of intralesionally injected TLR9-Agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J. Immunother. 31, 520-527
21. Iversen, P.L., Cornish, K.G., Iversen, L.J., Mata, J.E., aND Bylund, D.B. (1999). Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha(1)-Adrenergic receptor antagonists. Toxicol ApplPharmacol. 160, 289-296 (Pubitemid 29536377)
22. Janssen, R.S., Mangoo-Karim, R., Pergola, P.E., Girndt, M., Namini, H., Rahman, S., Bennett, S.R., Heyward, W.L., aND Martin, J.T. (2013). Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine 31, 5306-5313
23. Krieg, A.M. (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (Pubitemid 34293438)
24. Krieg, A.M. (2006). Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug. Disc. 5, 471-484 (Pubitemid 44136959)
25. Montaner, A.D., Insú A, A., ElíAS, F., Coronel, F., Denichilo, A., Rodriguez, J., Fló , J., Ló pez.R., Matzkin, B., Chasseing, N.A., Villar, M. and Zorzopulos, J. (2007) Montaner, A.D., Denichilo, A., RodríGuez, J.M., Hernando-Insua, A., Fló , J., Ló pez R.A., Sierra, V., Paolazzi, C., Larghi, O., Horn, D., Zorzopulos, and J., ElíAS, F. (2012). Immunomodulatory oligonucleotide IMT504 is a potent adjuvant of the rabies vaccine. World J. Vaccine 2, 182-188
26. Montaner, A.D., Denichilo, A., Rodríguez, J. M., Fló , J., Ló pez, R. A., Pontoriero, A., Savy, V., Baumeister, E., Frank, R., Zorzopulos, J., aND ElíAS, F. (2011). Addition of the immunostimulatory ODN IMT504 to a seasonal flu vaccine increases hemagglutinin antibody titers in young adult and elder rats, and expands the anti-HA antibody repertoire. Nucleic Acid Ther. 21, 265-274
27. Montaner, A.D., Insú A, A., ElíAS, F., Coronel, F., Denichilo, A., Rodriguez, J., Fló , J., Ló pez, R., Matzkin, B., Chasseing, Villar, M. and Zorzopulos, J. (2007). PyNTTTTGT Oligonucleotides as Tool in Tissue repair Procedures. Presented at Fifth Annual Meeting of the International Society for Stem Cell Research (ISSCR), June 17-20, Queensland, Australia
28. Monteith, D.K., Henry, S.P., Howard, R.B., Flournoy, S., Levin A.A., Bennett, C.F., aND Crooke, S.T. (1997). Immune stimulation a-class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des. 12, 421-432 (Pubitemid 27292377)
29. National RESEARCH COUNCIL (NRC 2011 Guide for the Care and Use of Laboratory Animals, 8th ed (National Academies Press, Washington DC
30. Prater, R.M., Johnson, V.J., Germolec, D.R., Luster, I.L., aND Holladay, S.D. (2007). Maternal treatment with a high dose of CpG ODN during gestation alters fetal craniofacial and distal limb development in C57BL/6 mice. Vaccine 24, 263-271 (Pubitemid 41790429)
31. Rodriguez, J.M., ElíAS, F., Fló , J., Ló pez, R.A., Zorzopulos, J., aND Montaner, A.D. (2006a). Immunostimulatory PyNTTTTGT oligodeoxynucleotides: Structural properties and refinement of the active motif. Oligonucleotides 16, 275-285 (Pubitemid 44763321)
32. Rodriguez, J.M., Elias, F., Montaner, A., Flo, J., Lopez, R.A., Zorzopulos, J., Franco, R.J., Lenial, S.P., Lopez, S.M., Pirpignani, M.L., et al. (2006b). Immunostimulatory PyNTTTTGT oligonucleotide IMT504 induce an immunogenic phenotype and apoptosis in chronic lymphocytic leukemia cells: Synergy with IL2 and independency of the mutational status of the Ig VH genes. Medicina (B Aires) 66, 9-16
33. RodríGUEZ, J.M., Marchisio, J., Ló pez, M., ElíAS, F., Montaner, A., Fló , J., Ló pez, R.A., aND Zorzopulos, J. (2005). Induction of high levels of GM-CSF secretion in human peripheral blood mononuclear cells by non-CpG immunostimulatory oligonucleotides. In: Experimental Biology. Presented at Thirtieth International Congress of Physiological Science, March 31-April 5, San Diego, CA
34. Sarmiento, U.M., Perez, J.R., aND Narayanan, R. (1994). In vivo toxicological effects of relA antisense phosphorothioate in CD-1 mice. Antisense Res. Dev.4, 99-107 (Pubitemid 24308378)
35. Takaoka, A., aND Taniguchi, T. (2008). Cytosolic DNA recognition for triggering innate immune responses. Adv. Drug. Deliv. Rev. 60, 847-857
36. Takaoka, A., Wang, Z., Choi, M.K., Yanai, H., Negishi, H., Ban, T., Lu, Y., Miyagishi, M., Kodama, T., Honda, K., Ohba, Y., aND Taniguchi, T. (2007). DAI (DLM-1 = ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448, 501-505 (Pubitemid 47123520)
37. Tucker, J.D., aND Preston, R.J. (1996). Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Mutat. Res. 365, 147-159 (Pubitemid 26344744)
38. Vollmer, J., aND Krieg, A.M. (2009). Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 61, 195-204
39. Wallace, T.L., Bazemore, D.J., aND Kornbrust COSSUM, P.A. (1996). Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J. Pharmacol. Exp.Ther. 278, 1306-1312 (Pubitemid 27166983)
40. Younis, H.S., Templin, M., Whitely, L.O., Kornbrust, D., Kim, T.W., aND Henry, S.P. (2013). Overview of the nonclinical development strategies and class-effects of oligonucleotide-based therapeutics. In: A Comprehensive Guide to Toxicology in Preclinical Drug Development. S. Ali Faqi, ed. (Academic Press, New York), pp. 647-664.